Physician profile
Shelley Anne Hall
NPI 1912961145
$253,895.32
in general payments reported to CMS, 2019-2025
26 companies · $93K in 2025
The $93K reported for 2025 was more than what 97% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $28K · 2021: $29K · 2022: $11K · 2023: $32K · 2024: $31K · 2025: $93K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $117K · Travel and Lodging: $16K · Honoraria: $14K · Food and Beverage: $8,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $117,156.75 |
| Travel and Lodging | $16,374.97 |
| Honoraria | $13,800.00 |
| Food and Beverage | $8,713.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $128,495.26 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, 2nd Gen Centrimag Primary Console |
| Cvrx, INC. | $49,353.09 | 2023-2025 | Barostim Neo System |
| Abiomed | $32,164.21 | 2019-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $24,769.10 | 2019-2025 | |
| Medtronic, INC. | $7,936.88 | 2021-2025 | Corevalve Evolut R |
| Sanofi-Aventis U.S. LLC | $6,709.28 | 2021-2022 | |
| Medtronic Vascular, INC. | $3,113.62 | 2019-2020 | |
| Heartflow, INC. | $350.00 | 2023 | Ffrct |
| Atricure, INC. | $200.91 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $183.72 | 2023-2024 | Lifevest |
| Alnylam Pharmaceuticals INC. | $150.32 | 2019-2023 | Amvuttra |
| Ancora Heart, INC. | $132.16 | 2025 | Accucinch |
| Zoll Respicardia, INC. | $101.43 | 2023 | Remede System |
| Merck Sharp & Dohme LLC | $96.65 | 2022-2023 | Verquvo |
| Amgen INC. | $21.89 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Briohealth Solutions, INC. | $20.29 | 2025 | Briovad |
| Nuwellis, INC. | $19.64 | 2020 | |
| W. L. Gore & Associates, INC. | $18.08 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $16.79 | 2019 | |
| Pfizer INC. | $15.87 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.51 | 2021 | |
| Abbvie INC. | $11.62 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shelley Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.